Royal Bank Of Canada Janux Therapeutics, Inc. Transaction History

Royal Bank Of Canada

$422 Billion
Q1 2024

A detailed history of Royal Bank Of Canada transactions in Janux Therapeutics, Inc. stock. As of the latest transaction made, Royal Bank Of Canada holds 1,587 shares of JANX stock, worth $66,479. This represents 0.0% of its overall portfolio holdings.

Number of Shares

1,587

Previous 4,697 66.21%

Holding current value

$66,479

Previous $50,000 18.0%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$7.93 - $49.75 $24,662 - $154,722	-3,110 Reduced 66.21%	1,587 $59,000
Q4 2023 Feb 14, 2024	BUY	$5.85 - $11.7 $7,604 - $15,209	1,300 Added 38.27%	4,697 $50,000
Q3 2023 Nov 14, 2023	BUY	$9.56 - $14.0 $15,429 - $22,596	1,614 Added 90.52%	3,397 $34,000
Q2 2023 Aug 14, 2023	BUY	$11.08 - $15.92 $9,118 - $13,102	823 Added 85.73%	1,783 $21,000
Q1 2023 May 15, 2023	SELL	$11.25 - $22.21 $13,736 - $27,118	-1,221 Reduced 55.98%	960 $11,000

Q4 2022 Feb 14, 2023	BUY	$11.1 - $18.26 $21,611 - $35,552	1,947 Added 832.05%	2,181 $28,000
Q3 2022 Nov 14, 2022	BUY	$10.82 - $16.84 $1,482 - $2,307	137 Added 141.24%	234 $3,000
Q2 2022 Aug 15, 2022	SELL	$9.52 - $15.65 $9,472 - $15,571	-995 Reduced 91.12%	97 $1,000
Q1 2022 May 16, 2022	SELL	$13.24 - $20.24 $24,626 - $37,646	-1,860 Reduced 63.01%	1,092 $16,000
Q4 2021 Feb 14, 2022	BUY	$15.44 - $27.32 $1,775 - $3,141	115 Added 4.05%	2,952 $58,000
Q3 2021 Nov 15, 2021	BUY	$20.7 - $34.69 $31,815 - $53,318	1,537 Added 118.23%	2,837 $61,000
Q2 2021 Aug 16, 2021	BUY	$18.58 - $25.37 $24,153 - $32,981	1,300 New	1,300 $32,000

Others Institutions Holding JANX

# of Institutions

123

Shares Held

25.3M

Call Options Held

92K

Put Options Held

161K

View Full List

About Janux Therapeutics, Inc.

Ticker JANX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 41,663,000
Market Cap $1.75B
Description
Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth ...

More about JANX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

News

Stay updated on Royal Bank Of Canada with notifications on news.

Account

Royal Bank Of Canada Janux Therapeutics, Inc. Transaction History